_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
OMCL
Primary Facts
Health Information Services
Name:
-
Sector:
- 31337.00K
Industry:
99.66
CEO:
Mr. Randall Lipps
Total Employees:
Mid Cap
Our Technological Advancement Rating
Our Rating:
0.962477955
-0.532176676
Omnicell, Inc. (XNAS:OMCL) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
OMNICELL, INC. (XNAS:OMCL)
One Month Price Target:
Six Month Price Target :
$100.25
Likely Price in One Year's Time:
Ticker:
$103.21
Likely Trading Range Today Under (Normal Volatility)
$100.12
Price Upper limit ($) :
$106.76
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P356
This week:
$94.87
This month :
$88.95
Other Primary facts
Market Cap:
44.29M
Market Cap Classification:
4.40B
Number of Shares
IPO Date:
D
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-15.39%
$78.25
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$111.65
13.71%
$87.67
$121.87
Medium risk (<10%) entry points
Buy Call
Sell Call
$106.13
Buy Put:
Sell Put:
$77.45
$93.19
$108.32
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Health Information Services
Sharpe Ratio:
OMCL, is amongst the top 40% highest yielding stocks in terms of daily returns
Comparison:
1.03%
0.988108079
Sharpe ratio is 98.81% higher than the industry
Average Returns/Yield of
Health Information Services
Daily returns:
1
Weekly returns:
0.06%
Monthly returns:
0.29%
Yearly returns:
13.72%
Comparison of returns:
1.704684121
Classification:
Average annual returns/yield (last 3 years) is 170.47% above industry average
Results of T-Test of Returns:
OMCL is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.68
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -10.41% lower than the market/S&P 500 average
Weekly Volatility:
2.37%
Monthly Volatility:
5.29%
Yearly Volatility:
10.59%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
46.14%
-45.98%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -45.98% below long-term volatility
Weekly VaR:
-4.80%
Monthly VaR:
-10.74%
How Much Can the price of
Health Information Services
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Medium (<50%)
Worst case (decline):
$81.38
This translates to price declining to:
-18%
This translates to price declining to:
-74.42%
Severe Crash Probability
-21.48%
What is Value at Risk (VaR)?
Risk Fundamentals
29.90%
OMCL is a 51.63% riskier investment compared to the market/S&P 500 & is 29.90% riskier than Nasdaq (IXIC)
OMCL is a 51.63% riskier investment compared to the market/S&P 500
Beta Examination of
Health Information Services
1.060
Expected beta in 1 year's time:
0.712
Expected beta in 3 year's time:
0.81
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--1.06
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is 21.79% above industry average
Beta Comparison & Analysis
Beta of competitors/peers::
1.016
-0.145
Average Industry Beta:
Beta is -14.47% lower than peers
0.217931034
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -5.83% below industry mean WACC
-47.08%
Alpha provided | Alpha Analysis
Alpha provided:
1.145
-1.822
2.110
Analysis of Cost of Capital of
Health Information Services
Equity cost of capital:
Alpha is 211% higher than market/& is unsustainably high
0.143
Unlevered (without debt) cost of capital:
Equity cost of capital is 14.26% above industry mean WACC
Before-tax cost of debt:
9.98%
After-tax cost of debt:
0.76%
Overall debt rating:
0.60%
Weighted average cost of capital (WACC):
0.76%
-5.83%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -51.44% below the industry mean
-91.61%
EPS:
Sixty-Five Million Eight Hundred Fifty-Five Thousand Twenty Dollars
Expected Annual growth rate of EPS (3Y):
Price to free cash flow ratio is -79.07% lower than the industry
-93.56%
Free cash flow (FCF) per share:
Price to book ratio is -15.92% below the industry mean
Growth rate in R&D investment/expenditure is -160.47% lower than the industry
-
Debt per share
Debt repayment rate in last quarter: 0.00%
EBITDA per share
Each employee generates -197% less EBITDA than industry average revenue per employee
Valuation Analysis Today of
Health Information Services
P/E Ratio:
Sustainable growth rate is -47.08% below industry average
P/E Ratio of Competitors/Peers:
79.57
-0.782269606
544.5241095
-0.816977801
$2.18
-
P/S (Price to Sales ratio):
$27.07
-0.514368631
P/B (Price to book value ratio):
Price to sales ratio is -51.44% below the industry mean
-
-0.790666608
Net income growth rate (3Y):
Annual revenue growth rate is -91.61% below industry average
-95.12%
Dividend Analysis
Net income growth rate is -95.12% lower than the industry average net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
32.41%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 4.8 years
Debt to assets ratio:
16.41%
Net debt to assets ratio:
3.47%
-94.86%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -94.86% below industry average
1.15
Looking forward:
Debt growth rate:
1.0x
-77.26%
0.00%
Analysis of Key Statistics
Correlation of price movement with the market:
13.13756945
Statistical significance of correlation:
-0.35%
Average Correlation of the industry with the market:
0.449
19.24%
R Squared (percentage of price movement explained by movement of the market):
0.449
Correlation of price movement with Nasdaq (^IXIC):
0.201
Covariance of price movement with the market:
-0.013
Kurtosis
-0.017
6.680
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
-0.251
Fundamental Analysis & Dupont Analysis of
Health Information Services
Gross Profit Margin Ratio:
582.42M
Operating Profit Margin Ratio:
Net profit margin is -133.59% lower than the industry
-135.02%
Net Profit Margin Ratio:
582.42M
Effective Tax Rate:
22.53%
-2.206789563
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -295.22% lower than the industry
-305.31%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -135.02% lower than the industry
-295.22%
Financial Leverage:
Interest coverage ratio is 115.49% more than industry average
Current Ratio:
Return on equity (ROE) is -305.31% lower than the industry
-0.855186931
Cash Conversion Cycle (days):
$0.84
0.040460122
Current ratio is -85.52% below industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 4.05% above industry average
-0.243471021
EBITDA generated per employee:
Each employee generates -24% less revenue than industry average revenue per employee
-1.973235299
Profit generated per employee:
$3.42
-124%
Free cash flow (FCF) generated per employee:
Each employee generates -124% less net income/profit than industry average revenue per employee
-1.652681264
Assets/Capital per employee
Each employee generates -165% less free cash flow than industry average revenue per employee
-1.652681264
Research & Development (R&D) Analysis
7.92%
-1.604735137
Competitors/Peer firms of
Health Information Services
$562.00
HEALTHEQUITY, INC. (XNAS:HQY)
SAREPTA THERAPEUTICS, INC. (XNAS:SRPT)
INTEGRA LIFESCIENCES HOLDINGS CORPORATION (XNAS:IART)
LHC GROUP, INC. (XNAS:LHCG)
IMMUNITYBIO, INC. (XNAS:IBRX)
STAAR SURGICAL COMPANY (XNAS:STAA)
ACADIA HEALTHCARE COMPANY, INC. (XNAS:ACHC)
TG THERAPEUTICS, INC. (XNAS:TGTX)
Current Analyst Ratings
$1.49
Strong buy�8%
Buy�13%
Hold�13%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
1.20B
616.59M
195%
84.67M
-
422.77M
-
-
1.12B
-
4.67M
88.89M
51%
- 13877.00K
- 16923.00K
20%
- 13877.00K
Statement of Cash Flow
Date:
Period:
8.21M
Differed Income Tax :
24.43M
Stock Based Compensation :
- 4858.00K
Change in Working Capital :
16.21M
Accounts Receivables:
- 62781.00K
Other Working Capital:
312.00K
Other Non-Cash Items:
- 4073.00K
Net Cash Provided by Operating Activities:
2.79M
Investments in PP&E:
- 15996.00K
Net Acquisitions:
- 11489.00K
Purchases of Investments:
- 3392.00K
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
265.01M
11.10M
276.11M
290.47M
137.06M
71.97M
775.60M
120.27M
740.43M
363.54M
19.05M
16.05M
87.65M
1.35B
-
2.12B
71.65M
576.08M
5.49M
176.76M
126.53M
951.01M
37.27M
7.35M
96.84M
-
1.05B
54.00K
393.29M
- 10962.0K
Value
507.44M
692.36M
1.07B
2.12B
30.15M
613.35M
-
-
- 3852.00K
- 18733.00K
-
-
- 52210.00K
-
20.09M
- 32119.00K
- 411.00K
- 67259.00K
288.36M
355.62M
- 15996.00K
- 15341.00K
Our Proprietary Portfolio Rating
Our Rating:
-45.63139267
Price Forecast/Expected Price in Next 5 Years of
Health Information Services
2023
2024
2025
2026
2027
426.8214298
$107.29
$457.21
$489.77
$524.64